Titre : | Is the indroduction of a priori control of advertising of medicinal products for healthcare professionals effective in reducing the risk of misure and off-label prescriptions ? |
Auteurs : | Tô Quynh Gandolphe |
Type de document : | Mémoire |
Année de publication : | 2013 |
Description : | 50p. / ann. |
Langues: | Anglais |
Classement : | EHMBA13/ (Master EHESP Executive Health MBA (master of business administration)) |
Mots-clés : | Médicament ; Contrôle médicament ; Dispensation médicament ; Distribution médicament ; Promotion santé ; Politique médicament ; Pharmacovigilance ; Sécurité sanitaire ; Publicité ; Laboratoire pharmaceutique |
Résumé : | Given that spending on marketing activities and promotion represents approximately 23% of sales of pharmaceutical companies, it has been established that their promotional efforts (advertising, sales force, conferences, medical journals ..) could have a negative influence on medical prescriptions going against health requirements as was the case in the Mediator affair; thus Law No. 2011-2012 of 29 December 2011 (Bertrand Act) restored a priori control of the advertising of drugs, measure that is intended to limit misuse and off-label prescriptions. The purpose of the study is to investigate the validity of this measure on the off-label prescribing and off-proper use. Survey of pharmaceutical companies (departments in charge of control of advertising) and professionals (doctors and pharmacists). We received 30 responses from firms, 25 pharmacists, four doctors. The majority of firms responded that the reform of the drug did not change either the content of their advertisements (70%) nor materials and channels of communication (87 %), however they have reduced the volume of their ads in favor of corporate communications and information on human disease and adapted their organization. Health professionals surveyed did not also noted changes in the content of advertising. It seems that the restoration of a priori control of advertisements for drugs is not a particularly relevant measure to limit misuse and off-label prescriptions. On the one hand, because advertising is only a small part of the promotional activities, some of which are not or poorly framed; on the other hand, the advertising in France was already good. Furthermore, this study has raised an issue regarding definitions and standards, which make it difficult to implement the regulations. |
Diplôme : | Master MBA Executive Health |
Plan de classement simplifié : | Master EHESP Executive Health (MBA) |
En ligne : | http://documentation.ehesp.fr/memoires/2013/ehmba/gandolphe.pdf |
Exemplaires (1)
Code-barres | Cote | Support | Localisation | Section | Disponibilité |
---|---|---|---|---|---|
071933 | EHMBA13/0004 | Mémoire | Rennes | Magasin | Empruntable Disponible |
Documents numériques (1)
ehmba/gandolphe URL |